Crisaborole After Eczema Improves: The Maintenance Trial

The US Eucrisa label directs twice-daily application for mild-to-moderate atopic dermatitis in people aged three months or older. After a clinical effect is achieved, it allows consideration of once-daily application. That change needs a plan for the skin that improves and for the skin that flares again.¹

Selection came first

Of 497 starters, 270 were randomized after up to eight weeks of twice-daily 2% crisaborole. Sixteen nonresponders were excluded, leaving 125 active/129 vehicle participants analyzed. Response required clear/almost-clear skin with a two-grade improvement and at least 50% improvement in the Eczema Area and Severity Index.²

Ask the prescriber what improvement would justify reducing applications in your case. Keep the start date and photographs of the same areas under similar lighting. Bring the tube, the instructions you have been following and a note of any applications missed because they stung or were difficult to fit into the day.

The first flare was the endpoint

Median time to first flare was 111 days with once-daily crisaborole versus 30 with once-daily vehicle (P=.0034). Flare meant clinician-rated disease becoming mild or worse. Both groups received twice-daily crisaborole for flares, up to 12 weeks, then resumed assigned maintenance after resolution.²

About 40% discontinued. Participants leaving before a flare were censored; they were not counted flare-free for the remaining year. Medians do not predict individual flare-free duration.²³

Pfizer funded the study and medical writing; several authors were employees/shareholders. No corticosteroid head-to-head comparison was performed.²

For the appointment, separate “How long until the first flare?” from “What do I do once one starts?” Write down which patches have returned, how much they itch and whether the prescribed treatment has changed. A date on the calendar makes a recurrence easier to discuss than trying to remember whether it was last month or the month before.

Put the maintenance plan in writing

The AAD’s⁴ adult topical guideline strongly recommends topical PDE-4 inhibitors, the class containing crisaborole. Its current guideline page also lists moisturizers and topical corticosteroids among recommended options. It does not choose one prescription for every patient.⁴

Ask the clinician to mark which skin areas receive medicine when they look clear, which receive moisturizer and what change should prompt a call. Confirm whether a new patch follows the same instructions. Do not copy the trial’s flare-treatment schedule as your own prescription.

Eucrisa is for external skin use, not in the eyes, mouth or vagina. Burning or stinging can occur. The label warns about hypersensitivity, including severe itching, swelling or redness at the application site or elsewhere: stop using it and contact the clinician immediately. Discuss pregnancy or breastfeeding; available human data are insufficient to establish safety.¹

If applications hurt, report where, how soon after application and how long the discomfort lasts. Ask whether the treatment, application method or diagnosis needs review before adding another product. Keep a contact number with the written plan so the next step is available when the clinic is closed.

“The Barrier, and the Three Jobs a Moisturizer Does” in Skin, Head to Toe explains moisture retention and the eczema evidence for moisturizers used alongside treatment. It is useful background for discussing the moisturizer portion of the plan; the prescribing instructions should come from your clinician.